Physician profile
Lee P Resta
NPI 1003882432
$1,264.51
in general payments reported to CMS, 2019-2025
28 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $137 · 2021: $216 · 2022: $125 · 2023: $326 · 2024: $101 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $245.30 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $121.75 | 2023-2024 | Calquence |
| Janssen Biotech, INC. | $113.97 | 2020-2025 | Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $88.45 | 2019-2025 | |
| Celgene Corporation | $70.29 | 2023-2025 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $62.10 | 2021-2023 | Imbruvica |
| Pfizer INC. | $59.13 | 2019-2025 | |
| Beigene USA, INC. | $42.76 | 2022-2023 | Brukinsa |
| Amgen INC. | $39.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.59 | 2019-2022 | |
| Kyowa Kirin, INC. | $32.28 | 2019-2020 | |
| Gilead Sciences, INC. | $31.60 | 2021-2022 | |
| Abbvie INC. | $31.36 | 2024 | |
| Merck Sharp & Dohme LLC | $29.82 | 2021-2023 | Keytruda |
| Celltrion USA INC. | $26.28 | 2023 | Vegzelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $26.05 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.95 | 2023 | Libtayo |
| Emd Serono, INC. | $21.36 | 2025 | |
| Glaxosmithkline, LLC. | $20.56 | 2021 | |
| Genentech USA, INC. | $19.04 | 2019 | |
| Incyte Corporation | $17.61 | 2023 | Jakafi |
| Cti Biopharma Corp. | $17.32 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $17.29 | 2023 | Orgovyx |
| Array Biopharma INC | $17.18 | 2025 | Braftovi, Lorbrena |
| Taiho Oncology, INC. | $15.01 | 2019 | |
| Exelixis INC. | $14.69 | 2023 | Cabometyx |
| Sirtex Medical INC | $14.07 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Resta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.